Literature DB >> 11704050

Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema.

H F Fine1, J Baffi, G F Reed, K G Csaky, R B Nussenblatt.   

Abstract

PURPOSE: To determine the association between cystoid macular edema and vascular endothelial growth factor concentration in the aqueous humor and plasma of uveitis patients.
METHODS: Cross-sectional study. Vascular endothelial growth factor concentrations were measured by enzyme-linked immunosorbent assay in the aqueous humor of 20 uveitis patients (9 with and 11 without cystoid macular edema), and in the plasma of 40 uveitis patients (20 with and 20 without cystoid macular edema) and 20 healthy volunteers.
RESULTS: Mean aqueous humor vascular endothelial growth factor concentrations for uveitis patients with and without cystoid macular edema were 152.3 and 109.5 pg/ml, respectively, P =.044. Mean plasma vascular endothelial growth factor concentrations in uveitis patients with and without cystoid macular edema and in healthy volunteers were 32.2, 29.6, and 55.0 pg/ml, respectively. Uveitis patients had lower plasma vascular endothelial growth factor levels than did healthy volunteers, P =.0002.
CONCLUSION: In uveitis patients, vascular endothelial growth factor concentration is increased in the aqueous humor of eyes with cystoid macular edema. It may be useful to investigate vascular endothelial growth factor antagonists as a treatment for uveitis-associated cystoid macular edema.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704050     DOI: 10.1016/s0002-9394(01)01103-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  25 in total

1.  Aqueous humor IL-8, IL-10, and VEGF levels in Fuchs' uveitis syndrome and Behçet's uveitis.

Authors:  Mert Simsek; Pinar Cakar Ozdal; Filiz Akbiyik; Mehmet Citirik; Nilufer Berker; Yasemin Ozdamar Erol; Pelin Yilmazbas
Journal:  Int Ophthalmol       Date:  2019-05-07       Impact factor: 2.031

2.  Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.

Authors:  Lea Scheppke; Edith Aguilar; Ray F Gariano; Ruth Jacobson; John Hood; John Doukas; Jon Cao; Glenn Noronha; Shiyin Yee; Sara Weis; Michael B Martin; Richard Soll; David A Cheresh; Martin Friedlander
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

3.  Vitreous levels of somatostatin in patients with chronic uveitic macular oedema.

Authors:  A Fonollosa; E Coronado; R Catalan; M Gutierrez; C Macia; M A Zapata; N Martinez-Alday; R Simo; J Garcia-Arumi
Journal:  Eye (Lond)       Date:  2012-08-10       Impact factor: 3.775

4.  Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial.

Authors:  Masoud Soheilian; Saeed Karimi; Alireza Ramezani; Talieh Montahai; Mehdi Yaseri; Roham Soheilian; Gholam A Peyman
Journal:  Int Ophthalmol       Date:  2014-07-19       Impact factor: 2.031

5.  Systemic contribution of inflammatory mediators to the severity of diabetic and uveitic macular edema.

Authors:  Marc Figueras-Roca; Jessica Matas; Víctor Llorens; Anna Sala-Puigdollers; Manuel Navarro; Javier Zarranz-Ventura; Alfredo Adán; Blanca Molins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-12       Impact factor: 3.117

6.  Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema.

Authors:  Marc H Levin; Maxwell Pistilli; Ebenezer Daniel; Sapna S Gangaputra; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; John H Kempen
Journal:  Ophthalmology       Date:  2013-12-12       Impact factor: 12.079

7.  Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt-Koyanagi-Harada disease.

Authors:  Han Sang Park; Ki Yup Nam; Jung Yeul Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-06       Impact factor: 3.117

8.  Bevacizumab in inflammatory eye disease.

Authors:  McGregor N Lott; Joyce C Schiffman; Janet L Davis
Journal:  Am J Ophthalmol       Date:  2009-08-05       Impact factor: 5.258

Review 9.  Emerging drugs for uveitis.

Authors:  Theresa Larson; Robert B Nussenblatt; H Nida Sen
Journal:  Expert Opin Emerg Drugs       Date:  2011-01-06       Impact factor: 4.191

10.  CD4+Foxp3+ T-regulatory cells in noninfectious uveitis.

Authors:  Steven Yeh; Zhuqing Li; Farzin Forooghian; Frank S Hwang; Matthew A Cunningham; Seth Pantanelli; Julie C Lew; Keith K Wroblewski; Susan Vitale; Robert B Nussenblatt
Journal:  Arch Ophthalmol       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.